Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting 20 enrolled ImmunityBio, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Open-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Timeline

Start: 2026-04
Primary completion: 2027-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19 t-haNK	Cell therapy	—	Intravenous
Subject	N-803	Protein / enzyme biologic	—	Subcutaneous
Subject	Rituximab	Monoclonal antibody	—	—

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications